The purpose of this study is to assess the safety and effectiveness of two investigational drugs when given together in patients with advanced ovarian cancer or hormone receptor-positive breast cancer. The drugs are BYL719 and AMG 479 (ganitumab).
BYL719 is an inhibitor of PI3 kinase, an enzyme which fuels the growth of several types of cancer. It is taken orally (by mouth). AMG 479 is designed to bind to a protein on the surface of cancer cells called insulin-like growth factor receptor 1 (IGF-1R), inhibiting its ability to interact with other proteins and stopping cancer cell growth in laboratory studies. AMG 479 is given intravenously (by vein).
It is believed that giving BYL719 and AMG 479 together may be more effective than giving these two drugs alone.